Register entry
- Registered sites
- 0
- Active NDC listings
- 6
- Live patents
- 14
- Exclusivities
- 1
- Countries
- 0
Catalogue
Drug listings by form and route
66 active NDC listings: 6 human prescription drug. By marketing category: BLA 4, NDA 2.
| Dosage form | NDCs |
|---|---|
| injection, powder, lyophilized, for solution | 3 |
| tablet | 2 |
| injection, powder, for solution | 1 |
| Route | NDCs |
|---|---|
| intravenous | 4 |
| oral | 2 |
| Labeller name on the listing | NDCs |
|---|---|
| seagen inc. | 6 |
Exclusivity
Patents and exclusivities
14| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 9693989 | TUKYSAtucatinib | product | May 2027 |
| 9457093 | TUKYSAtucatinib | product | Oct 2032 |
| 11504370 | TUKYSAtucatinib | use | Mar 2033 |
| 8648087 | TUKYSAtucatinib | substance, product | Apr 2034 |
| 11207324 | TUKYSAtucatinib | use | Apr 2038 |
| 11666572 | TUKYSAtucatinib | use | Apr 2038 |
| 12048698 | TUKYSAtucatinib | use | Apr 2038 |
| Product | Exclusivity | Until |
|---|---|---|
| TUKYSATUCATINIB | ODE-422 Orphan drug | Jan 2030 |
Catalogue
Marketed products
6| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| ADCETRIS | brentuximab vedotin | injection, powder, lyophilized, for solution, intravenous | 51144-050BLA |
| PADCEV EJFV | ENFORTUMAB VEDOTIN | injection, powder, lyophilized, for solution, intravenous | 51144-020BLA |
| PADCEV EJFV | ENFORTUMAB VEDOTIN | injection, powder, lyophilized, for solution, intravenous | 51144-030BLA |
| TIVDAK | tisotumab vedotin | injection, powder, for solution, intravenous | 51144-003BLA |
| TUKYSA | tucatinib | tablet, oral | 51144-001NDA |
| TUKYSA | tucatinib | tablet, oral | 51144-002NDA |
Enquiry
Common questions
- Is SEAGEN INC. FDA approved?
- SEAGEN INC. holds no registered establishment of its own; 6 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does SEAGEN INC. make?
- 6 products are listed under SEAGEN INC. in the openFDA NDC Directory, most often as injection, powder, lyophilized, for solution; tablet; injection, powder, for solution. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.